Symbols / GLMD
GLMD Chart
About
Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, a first-in-class synthetic fatty acid-bile acid conjugate molecule which is in Phase III study for oral treatment for non-alcoholic steato-hepatitis (NASH) in patients who are overweight or obese and have prediabetes or type II diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine. Further, the company develops MyBiotics which is in pre-clinical trials for NASH and fibrosis. It has a license agreement with Samil Pharma. Co., Ltd. for the commercialization of Aramchol in the Republic of Korea; and a collaboration agreement with OnKai for its AI platform. Galmed Pharmaceuticals Ltd. was founded in 2000 and is headquartered in Ramat Gan, Israel.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 3.78M |
| Enterprise Value | -15.90M | Income | -8.70M | Sales | — |
| Book/sh | 3.49 | Cash/sh | 3.48 | Dividend Yield | — |
| Payout | 0.00% | Employees | 3 | IPO | — |
| P/E | — | Forward P/E | -0.56 | PEG | — |
| P/S | — | P/B | 0.16 | P/C | — |
| EV/EBITDA | 2.25 | EV/Sales | — | Quick Ratio | 7.93 |
| Current Ratio | 7.98 | Debt/Eq | — | LT Debt/Eq | — |
| EPS (ttm) | -3.44 | EPS next Y | -1.03 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2025-11-26 08:00 | ROA | -20.90% |
| ROE | -46.34% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 6.58M |
| Shs Float | 5.42M | Short Float | 1.03% | Short Ratio | 0.71 |
| Short Interest | — | 52W High | 3.50 | 52W Low | 0.53 |
| Beta | 0.38 | Avg Volume | 108.97K | Volume | 36.88K |
| Target Price | — | Recom | None | Prev Close | $0.55 |
| Price | $0.57 | Change | 3.70% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
—
Mean price target
2. Current target
$0.58
Latest analyst target
3. DCF / Fair value
$-12.51
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$0.58
Low
—
High
—
Mean
—
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2025-04-04 | down | Maxim Group | Buy → Hold | — |
| 2023-07-24 | up | Maxim Group | Hold → Buy | $4 |
| 2022-08-08 | down | Maxim Group | Buy → Hold | — |
| 2022-08-08 | down | Canaccord Genuity | Buy → Hold | $1 |
| 2022-05-18 | down | Raymond James | Outperform → Market Perform | — |
| 2022-05-03 | down | HC Wainwright & Co. | Buy → Neutral | — |
| 2022-05-03 | main | Raymond James | — → Outperform | $5 |
| 2021-05-17 | main | Canaccord Genuity | — → Buy | $21 |
| 2021-03-19 | main | HC Wainwright & Co. | — → Buy | $25 |
| 2021-01-08 | main | Raymond James | — → Outperform | $17 |
| 2020-11-25 | main | Canaccord Genuity | — → Buy | $20 |
| 2020-05-22 | down | B. Riley Securities | Buy → Neutral | $8 |
| 2020-05-15 | main | Raymond James | — → Outperform | $20 |
| 2020-03-13 | main | Stifel | — → Buy | $25 |
| 2020-03-13 | main | B. Riley Securities | — → Buy | $11 |
| 2020-02-04 | init | Craig-Hallum | — → Buy | $18 |
| 2019-07-22 | init | Laidlaw & Co. | — → Buy | $25 |
| 2018-12-12 | init | B. Riley Securities | — → Buy | $28 |
| 2018-07-20 | init | Raymond James | — → Outperform | $26 |
| 2018-07-13 | init | Stifel | — → Buy | $35 |
- Galmed (NASDAQ: GLMD) AM-001 shows 5-fold, 3-fold Aramchol bioavailability improvement - Stock Titan ue, 18 Nov 2025 08
- Galmed Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update - PR Newswire hu, 22 May 2025 07
- Galmed Pharmaceuticals Reveals Promising Results in Oncology Drug Combination Study - TipRanks Mon, 17 Nov 2025 08
- Galmed stock soars after promising cancer treatment research results - Investing.com Nigeria Mon, 17 Nov 2025 08
- Galmed Pharmaceuticals: Is It A Turnaround Story? - timothysykes.com Mon, 17 Nov 2025 08
- Galmed Pharmaceuticals (GLMD) Soars on New Cancer Drug Combo Data: What Today’s Breakthrough Means for Investors – November 17, 2025 - TechStock² Mon, 17 Nov 2025 08
- Galmed Pharmaceuticals Sets March 4 Vote on Reverse Stock Split to Address Nasdaq Listing Deficiency - TipRanks Mon, 09 Feb 2026 08
- symbol__ Stock Quote Price and Forecast - CNN ue, 26 Mar 2024 13
- Galmed Pharma Shares Jump 10% On Cancer Drug Data: Retail Traders Turn ‘Extremely Bullish’ - Stocktwits ue, 06 May 2025 07
- GLMD’s Unexpected Rise: What’s Fueling the Surge? - StocksToTrade Mon, 17 Mar 2025 07
- Galmed Pharmaceuticals Surges 400%: What's Behind the Explosion? - MarketBeat ue, 17 Sep 2024 07
- Galmed Pharmaceuticals Soars Nearly 500% Amid Nasdaq Compliance and Short Squeeze - Nasdaq Wed, 18 Sep 2024 07
- Wall Street Favorites: 3 Penny Stocks With Strong Buy Ratings for April 2024 - Yahoo Finance Wed, 10 Apr 2024 07
- Galmed Pharmaceuticals Receives Nasdaq Minimum Bid Price Deficiency Notice - TipRanks Fri, 30 Jan 2026 08
- GLMD - Galmed Pharmaceu Latest Stock News & Market Updates - Stock Titan Wed, 16 Sep 2020 09
Insider Transactions
No recent insider transactions.
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | -5.08M | -7.68M | -17.13M | -32.73M |
| TotalUnusualItems | -1.12M | 216.00K | -490.00K | -105.00K |
| TotalUnusualItemsExcludingGoodwill | -1.12M | 216.00K | -490.00K | -105.00K |
| NetIncomeFromContinuingOperationNetMinorityInterest | -7.52M | -6.91M | -17.87M | -32.47M |
| ReconciledDepreciation | 83.00K | 31.00K | 35.00K | 42.00K |
| EBITDA | -6.20M | -7.46M | -17.62M | -32.84M |
| EBIT | -6.28M | -7.49M | -17.65M | -32.88M |
| NetInterestIncome | -122.00K | 364.00K | 275.00K | 519.00K |
| InterestIncome | 503.00K | 375.00K | 297.00K | 562.00K |
| NormalizedIncome | -6.40M | -7.13M | -17.38M | -32.36M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -7.52M | -6.91M | -17.87M | -32.47M |
| TotalExpenses | 6.28M | 7.49M | 17.65M | 32.88M |
| RentExpenseSupplemental | 117.00K | 261.00K | 401.00K | 530.00K |
| TotalOperatingIncomeAsReported | -6.28M | -7.49M | -17.65M | -32.88M |
| DilutedAverageShares | 930.82K | 230.79K | 139.68K | 136.65K |
| BasicAverageShares | 930.82K | 230.79K | 139.68K | 136.65K |
| DilutedEPS | -8.08 | -30.00 | -127.80 | -237.60 |
| BasicEPS | -8.08 | -30.00 | -127.80 | -237.60 |
| DilutedNIAvailtoComStockholders | -7.52M | -6.91M | -17.87M | -32.47M |
| NetIncomeCommonStockholders | -7.52M | -6.91M | -17.87M | -32.47M |
| NetIncome | -7.52M | -6.91M | -17.87M | -32.47M |
| NetIncomeIncludingNoncontrollingInterests | -7.52M | -6.91M | -17.87M | -32.47M |
| NetIncomeContinuousOperations | -7.52M | -6.91M | -17.87M | -32.47M |
| PretaxIncome | -7.52M | -6.91M | -17.87M | -32.47M |
| OtherIncomeExpense | -1.12M | 216.00K | -490.00K | -105.00K |
| SpecialIncomeCharges | -1.15M | 0.00 | 0.00 | |
| WriteOff | 1.15M | 0.00 | 0.00 | |
| GainOnSaleOfSecurity | 28.00K | 216.00K | -490.00K | -105.00K |
| NetNonOperatingInterestIncomeExpense | -122.00K | 364.00K | 275.00K | 519.00K |
| TotalOtherFinanceCost | 625.00K | 11.00K | 22.00K | 43.00K |
| InterestIncomeNonOperating | 503.00K | 375.00K | 297.00K | 562.00K |
| OperatingIncome | -6.28M | -7.49M | -17.65M | -32.88M |
| OperatingExpense | 6.28M | 7.49M | 17.65M | 32.88M |
| ResearchAndDevelopment | 2.98M | 3.57M | 12.99M | 27.22M |
| SellingGeneralAndAdministration | 3.30M | 3.92M | 4.66M | 5.66M |
| GeneralAndAdministrativeExpense | 3.30M | 3.92M | 4.66M | 5.66M |
| OtherGandA | 896.00K | 908.00K | 1.08M | 1.14M |
| InsuranceAndClaims | 389.00K | 677.00K | 1.09M | 1.15M |
| RentAndLandingFees | 117.00K | 261.00K | 401.00K | 530.00K |
| SalariesAndWages | 1.90M | 2.08M | 2.08M | 2.84M |
| TotalRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| OperatingRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 1.66M | 420.44K | 140.02K | 139.38K |
| ShareIssued | 1.66M | 420.44K | 140.02K | 139.38K |
| TotalDebt | 0.00 | 41.00K | 215.00K | 229.00K |
| TangibleBookValue | 16.33M | 13.88M | 13.42M | 30.50M |
| InvestedCapital | 16.33M | 13.88M | 13.42M | 30.50M |
| WorkingCapital | 13.95M | 10.49M | 11.63M | 30.18M |
| NetTangibleAssets | 16.33M | 13.88M | 13.42M | 30.50M |
| CapitalLeaseObligations | 0.00 | 41.00K | 215.00K | 229.00K |
| CommonStockEquity | 16.33M | 13.88M | 13.42M | 30.50M |
| TotalCapitalization | 16.33M | 13.88M | 13.42M | 30.50M |
| TotalEquityGrossMinorityInterest | 16.33M | 13.88M | 13.42M | 30.50M |
| StockholdersEquity | 16.33M | 13.88M | 13.42M | 30.50M |
| GainsLossesNotAffectingRetainedEarnings | -416.00K | -454.00K | -745.00K | -171.00K |
| OtherEquityAdjustments | -416.00K | -454.00K | -745.00K | -171.00K |
| RetainedEarnings | -200.47M | -192.95M | -186.04M | -168.17M |
| AdditionalPaidInCapital | 216.47M | 207.08M | 200.14M | 198.77M |
| CapitalStock | 742.00K | 209.00K | 70.00K | 70.00K |
| CommonStock | 742.00K | 209.00K | 70.00K | 70.00K |
| TotalLiabilitiesNetMinorityInterest | 2.17M | 2.75M | 3.14M | 6.11M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 0.00 | 0.00 | 44.00K | 229.00K |
| LongTermDebtAndCapitalLeaseObligation | 0.00 | 44.00K | 229.00K | |
| LongTermCapitalLeaseObligation | 0.00 | 44.00K | 229.00K | |
| CurrentLiabilities | 2.17M | 2.75M | 3.09M | 5.88M |
| CurrentDebtAndCapitalLeaseObligation | 41.00K | 171.00K | ||
| CurrentCapitalLeaseObligation | 0.00 | 41.00K | 171.00K | |
| PensionandOtherPostRetirementBenefitPlansCurrent | 603.00K | 571.00K | 160.00K | |
| PayablesAndAccruedExpenses | 1.57M | 2.14M | 2.76M | 5.88M |
| CurrentAccruedExpenses | 256.00K | 259.00K | 196.00K | |
| Payables | 1.31M | 1.88M | 2.57M | 5.88M |
| OtherPayable | 6.00K | 7.00K | 1.01M | |
| AccountsPayable | 1.31M | 1.88M | 2.56M | 4.87M |
| TotalAssets | 18.50M | 16.63M | 16.56M | 36.60M |
| TotalNonCurrentAssets | 2.38M | 3.39M | 1.84M | 551.00K |
| NonCurrentNoteReceivables | 257.00K | 0.00 | ||
| InvestmentsAndAdvances | 2.12M | 3.27M | 1.50M | 0.00 |
| InvestmentinFinancialAssets | 0.00 | 1.50M | 0.00 | |
| AvailableForSaleSecurities | 1.50M | |||
| LongTermEquityInvestment | 2.12M | 3.27M | 0.00 | |
| InvestmentsinAssociatesatCost | 2.12M | 3.27M | 0.00 | |
| NetPPE | 0.00 | 125.00K | 337.00K | 551.00K |
| AccumulatedDepreciation | -1.10M | -1.02M | -988.00K | -957.00K |
| GrossPPE | 1.10M | 1.14M | 1.32M | 1.51M |
| Leases | 236.00K | 235.00K | 235.00K | 231.00K |
| OtherProperties | 737.00K | 779.00K | 960.00K | 1.14M |
| MachineryFurnitureEquipment | 130.00K | 130.00K | 130.00K | 134.00K |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 16.12M | 13.24M | 14.72M | 36.05M |
| RestrictedCash | 121.00K | 117.00K | 114.00K | 114.00K |
| PrepaidAssets | 463.00K | 315.00K | 668.00K | 1.05M |
| Receivables | 209.00K | 165.00K | 157.00K | 79.00K |
| OtherReceivables | 209.00K | 165.00K | 157.00K | 79.00K |
| CashCashEquivalentsAndShortTermInvestments | 15.33M | 12.64M | 13.79M | 34.81M |
| OtherShortTermInvestments | 10.68M | 9.78M | 11.77M | 31.93M |
| CashAndCashEquivalents | 4.65M | 2.86M | 2.02M | 2.88M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -5.88M | -6.14M | -18.50M | -32.90M |
| IssuanceOfCapitalStock | 8.79M | 6.18M | 70.00K | 17.37M |
| CapitalExpenditure | -4.00K | -11.00K | ||
| EndCashPosition | 4.77M | 2.98M | 2.13M | 3.00M |
| BeginningCashPosition | 2.98M | 2.13M | 3.00M | 7.06M |
| ChangesInCash | 1.79M | 848.00K | -868.00K | -4.06M |
| FinancingCashFlow | 8.79M | 6.18M | 70.00K | 17.37M |
| CashFlowFromContinuingFinancingActivities | 8.79M | 6.18M | 70.00K | 17.37M |
| ProceedsFromStockOptionExercised | 0.00 | 0.00 | 0.00 | |
| NetCommonStockIssuance | 8.79M | 6.18M | 70.00K | 17.37M |
| CommonStockIssuance | 8.79M | 6.18M | 70.00K | 17.37M |
| InvestingCashFlow | -1.11M | 800.00K | 17.56M | 11.46M |
| CashFlowFromContinuingInvestingActivities | -1.11M | 800.00K | 17.56M | 11.46M |
| NetOtherInvestingChanges | -250.00K | -1.00K | ||
| NetInvestmentPurchaseAndSale | -861.00K | 2.30M | 17.57M | 11.47M |
| SaleOfInvestment | 5.50M | 8.63M | 21.44M | 25.04M |
| PurchaseOfInvestment | -6.37M | -6.33M | -3.87M | -13.57M |
| NetBusinessPurchaseAndSale | 0.00 | -1.50M | 0.00 | 0.00 |
| PurchaseOfBusiness | 0.00 | -1.50M | 0.00 | 0.00 |
| NetPPEPurchaseAndSale | 0.00 | 0.00 | -4.00K | -11.00K |
| PurchaseOfPPE | 0.00 | 0.00 | -4.00K | -11.00K |
| OperatingCashFlow | -5.88M | -6.14M | -18.50M | -32.89M |
| CashFlowFromContinuingOperatingActivities | -5.88M | -6.14M | -18.50M | -32.89M |
| ChangeInWorkingCapital | -721.00K | 79.00K | -2.45M | -2.45M |
| ChangeInOtherWorkingCapital | 7.00K | -53.00K | ||
| ChangeInPayablesAndAccruedExpense | -536.00K | -213.00K | -2.75M | -2.14M |
| ChangeInPayable | -536.00K | -213.00K | -2.75M | -2.14M |
| ChangeInAccountPayable | -571.00K | -681.00K | -2.31M | -2.17M |
| ChangeInReceivables | -192.00K | 345.00K | 300.00K | -313.00K |
| OtherNonCashItems | 611.00K | 6.00K | -36.00K | 13.00K |
| StockBasedCompensation | 531.00K | 892.00K | 1.30M | 1.89M |
| UnrealizedGainLossOnInvestmentSecurities | -265.00K | 0.00 | 0.00 | |
| AssetImpairmentCharge | 1.15M | 0.00 | 0.00 | |
| AmortizationOfSecurities | -17.00K | 19.00K | -2.00K | 121.00K |
| DepreciationAmortizationDepletion | 83.00K | 31.00K | 35.00K | 42.00K |
| DepreciationAndAmortization | 83.00K | 31.00K | 35.00K | 42.00K |
| Depreciation | 83.00K | 31.00K | 35.00K | 42.00K |
| OperatingGainsLosses | 5.00K | 13.00K | 523.00K | -37.00K |
| EarningsLossesFromEquityInvestments | -7.00K | 0.00 | 0.00 | |
| GainLossOnInvestmentSecurities | 12.00K | 13.00K | 523.00K | -37.00K |
| NetIncomeFromContinuingOperations | -7.52M | -6.91M | -17.87M | -32.47M |
SEC Filings
No SEC filings found for this symbol (may be non-US or ticker not in SEC index).
Public Trades for GLMD
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|